RECRUITING

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Official Title

Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study

Quick Facts

Study Start:2021-11-19
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05116930

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 54 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).
  2. * Onset of HA within 72 hours of delivery.
  1. * Patient refusal.
  2. * Visual analog scale (NRS) score \< 4.
  3. * History of migraine headaches.
  4. * Asthma.
  5. * Arrhythmia.
  6. * Heart block.
  7. * Myasthenia gravis.
  8. * Inability to understand pain scores and other questionnaires.
  9. * Inability to speak English.
  10. * Contraindication to acetaminophen or NSAIDs.
  11. * Temperature \> 38.5 C.
  12. * Prior EBP done for this HA.

Contacts and Locations

Principal Investigator

Mark Rollins, MD, PhD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Mark Rollins, MD, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-19
Study Completion Date2024-12

Study Record Updates

Study Start Date2021-11-19
Study Completion Date2024-12

Terms related to this study

Additional Relevant MeSH Terms

  • Post-Dural Puncture Headache